The Food and Drug Administration in the United States (U.S. FDA) has previously commented on the need for post-marketing surveillance studies for issues of bladder cancer related to SGLT-2 inhibitors based on the concern about chronic exposure of urinary tract with glycosuria [12]. The gene discussed is SLC5A2; the disease is urinary bladder cancer.